1. Home
  2. AMCI vs MXCT Comparison

AMCI vs MXCT Comparison

Compare AMCI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AMCI

AMC Robotics Corporation Common Stock

N/A

Current Price

$6.48

Market Cap

150.0M

Sector

Finance

ML Signal

N/A

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$0.77

Market Cap

86.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCI
MXCT
Founded
2021
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
150.0M
86.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AMCI
MXCT
Price
$6.48
$0.77
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
67.4K
1.4M
Earning Date
01-01-0001
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$38,627,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$9.64
P/E Ratio
$33.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.60
$0.64
52 Week High
$15.75
$3.58

Technical Indicators

Market Signals
Indicator
AMCI
MXCT
Relative Strength Index (RSI) 48.82 34.49
Support Level $5.65 $0.75
Resistance Level $6.99 $1.79
Average True Range (ATR) 0.65 0.06
MACD 0.13 0.03
Stochastic Oscillator 35.71 67.86

Price Performance

Historical Comparison
AMCI
MXCT

About AMCI AMC Robotics Corporation Common Stock

AMC Robotics Corp is an artificial intelligence services company that develops robotic solutions designed to support operational efficiency across sectors such as logistics and manufacturing. The company develops robotics and automation technologies designed to improve logistics operations. Its robots use sensors and visual AI to support real-time decision-making, contributing to safer and more efficient warehouse operations. It builds autonomous robots for use in logistics and warehousing.

About MXCT MaxCyte Inc.

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Share on Social Networks: